MetaCap

BGM Group (BGM) vs Immunic (IMUX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immunic (IMUX) has outperformed BGM Group (BGM) over the past year, gaining 1.9% versus a loss of 96.7%. Over five years, IMUX leads with a -91.9% price change compared with -98.3% for BGM. Immunic is the larger company by market cap ($111.0 million vs $108.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BGM-96.73%IMUX+7.73%
+159%+25%-109%
Nov 21, 20251 yearNov 19, 2026
BGM-98.38%IMUX-92.54%
+52%-27%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BGM versus IMUX key metrics
MetricBGMIMUX
Share price$8.13$6.99
Market cap$108.57M$111.01M
1-day change0.00%-5.41%
YTD return-92.77%+30.90%
1-year return-96.73%+1.90%
5-year return-98.31%-91.88%
EPS (TTM)$-4.80$-3.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$37.92M—
Revenue growth (YoY)+51.09%—
Net income (latest FY)$-19.94M$-97.17M
Gross margin16.64%—
Operating margin-33.18%—
Net margin-52.59%—
52-week high$263.70$17.43
52-week low$0.00$5.06
Distance from 52-week high-96.92%-59.90%
Analyst consensus—strong_buy
Avg. price target upside—+508.73%
Average volume6.18K343.44K
Shares outstanding12.69M15.88M
Employees—100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMUX has outperformed BGM by 98.6 percentage points over the past year.

About BGM Group

BGM stock →

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.

Health Care · Biotechnology: Pharmaceutical Preparations

About Immunic

IMUX stock →

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

BGM vs IMUX FAQ

Which is bigger, BGM Group or Immunic?

Immunic (IMUX) is larger, with a market capitalization of $111.01M compared with $108.57M for BGM Group (BGM).

Which stock has performed better over the past year, BGM or IMUX?

IMUX returned +1.90% over the past 12 months, compared with -96.73% for BGM (price return, excluding dividends). Past performance does not predict future results.

Are BGM Group and Immunic in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons